Alegret JM - Search Results

1

Cost-effectiveness of direct oral anticoagulants versus vitamin K antagonist in atrial fibrillation: A study protocol using Real-World Data from Catalonia (FantasTIC Study).

Hernández Rojas Z, Dalmau Llorca MR, Aguilar Martín C, Gonçalves AQ, Casajuana M, Fernández-Sáez J, Rodríguez Cumplido D, Forcadell Drago E, Carrasco-Querol N, Pepió Vilaubí JM, Alegret JM. Hernández Rojas Z, et al. Among authors: alegret jm. Medicine (Baltimore). 2020 Sep 4;99(36):e22054. doi: 10.1097/MD.0000000000022054. Medicine (Baltimore). 2020. PMID: 32899067 Free PMC article. Clinical Trial.

2

Results, barriers and enablers in atrial fibrillation case finding: barriers in opportunistic atrial fibrillation case finding-a cross-sectional study.

Ballesta-Ors J, Clua-Espuny JL, Gentille-Lorente DI, Lechuga-Duran I, Fernández-Saez J, Muria-Subirats E, Blasco-Mulet M, Lorman-Carbo B, Alegret JM. Ballesta-Ors J, et al. Among authors: alegret jm. Fam Pract. 2020 Sep 5;37(4):486-492. doi: 10.1093/fampra/cmaa023. Fam Pract. 2020. PMID: 32219320

3

New oral anticoagulants vs vitamin K antagonists: benefits for health-related quality of life in patients with atrial fibrillation.

Alegret JM, Viñolas X, Arias MA, Martínez-Rubio A, Rebollo P, Ràfols C, Martínez-Sande JL. Alegret JM, et al. Int J Med Sci. 2014 May 1;11(7):680-4. doi: 10.7150/ijms.8916. eCollection 2014. Int J Med Sci. 2014. PMID: 24843316 Free PMC article.

4

Gender Differences in Patients with Atrial Fibrillation Undergoing Electrical Cardioversion.

Alegret JM, Viñolas X, Martínez-Rubio A, Pedrote A, Beiras X, García-Sacristán JF, Crespo-Mancebo F, Ruiz-Mateas F. Alegret JM, et al. J Womens Health (Larchmt). 2015 Jun;24(6):466-70. doi: 10.1089/jwh.2014.5014. Epub 2015 May 15. J Womens Health (Larchmt). 2015. PMID: 25978301

5

Trends in the use of electrical cardioversion for atrial fibrillation: influence of major trials and guidelines on clinical practice.

Alegret JM, Viñolas X, Romero-Menor C, Pons S, Villuendas R, Calvo N, Pérez-Rodon J, Sabaté X; REVERCAT study investigators. Alegret JM, et al. BMC Cardiovasc Disord. 2012 Jun 18;12:42. doi: 10.1186/1471-2261-12-42. BMC Cardiovasc Disord. 2012. PMID: 22708978 Free PMC article.

6

Improvement in Atrial Fibrillation-Related Symptoms After Cardioversion: Role of NYHA Functional Class and Maintenance of Sinus Rhythm.

Ferre-Vallverdu M, Ligero C, Vidal-Perez R, Martinez-Rubio A, Vinolas X, Alegret JM. Ferre-Vallverdu M, et al. Among authors: alegret jm. Clin Interv Aging. 2021 Apr 29;16:739-745. doi: 10.2147/CIA.S305619. eCollection 2021. Clin Interv Aging. 2021. PMID: 33953552 Free PMC article.

7

Predictors of success and effect of biphasic energy on electrical cardioversion in patients with persistent atrial fibrillation.

Alegret JM, Viñolas X, Sagristá J, Hernandez-Madrid A, Pérez L, Sabaté X, Mont L, Medina A; REVERSE Study Investigators. Alegret JM, et al. Europace. 2007 Oct;9(10):942-6. doi: 10.1093/europace/eum107. Epub 2007 Jun 2. Europace. 2007. PMID: 17545688

8

The relevance of the association between inflammation and atrial fibrillation.

Alegret JM, Aragonès G, Elosua R, Beltrán-Debón R, Hernández-Aguilera A, Romero-Menor C, Camps J, Joven J. Alegret JM, et al. Eur J Clin Invest. 2013 Apr;43(4):324-31. doi: 10.1111/eci.12047. Epub 2013 Feb 11. Eur J Clin Invest. 2013. PMID: 23397981 Free article.

9

[Clinical characteristics of patients with persistent atrial fibrillation referred for cardioversion: Spanish Cardioversion Registry (REVERSE)].

Alegret JM, Viñolas X, Sagristá J, Hernández-Madrid A, Berruezo A, Moya A, Martínez Sande JL, Pastor A; nombre de los investigadores del Estudio REVERSE. Alegret JM, et al. Rev Esp Cardiol. 2008 Jun;61(6):630-4. Rev Esp Cardiol. 2008. PMID: 18570785 Free article. Spanish.

10

Utility of Amiodarone Pre-Treatment as a Facilitator of the Acute Success of Electrical Cardioversion in Persistent Atrial Fibrillation.

Alegret JM, Viñolas X, Tajes H, Valdovinos P, Palomares R, Arias MA, Bazán V. Alegret JM, et al. Cardiovasc Drugs Ther. 2020 Feb;34(1):89-94. doi: 10.1007/s10557-019-06934-5. Cardiovasc Drugs Ther. 2020. PMID: 32096001

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

61 results

Search Page